S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
AMZN   1,736.43 (+0.26%)
NVDA   186.53 (+0.29%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
AMZN   1,736.43 (+0.26%)
NVDA   186.53 (+0.29%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
Log in

Penumbra Stock Price, News & Analysis (NYSE:PEN)

$144.74
-1.20 (-0.82 %)
(As of 10/14/2019 04:00 PM ET)
Today's Range
$143.02
Now: $144.74
$145.86
50-Day Range
$131.82
MA: $142.06
$151.26
52-Week Range
$110.84
Now: $144.74
$185.70
Volume6,603 shs
Average Volume786,921 shs
Market Capitalization$5.04 billion
P/E Ratio283.80
Dividend YieldN/A
Beta0.71
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-748-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$444.94 million
Cash Flow$0.72 per share
Book Value$12.24 per share

Profitability

Net Income$6.60 million

Miscellaneous

Employees2,200
Market Cap$5.04 billion
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.


Penumbra (NYSE:PEN) Frequently Asked Questions

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

How were Penumbra's earnings last quarter?

Penumbra Inc (NYSE:PEN) issued its quarterly earnings results on Tuesday, August, 6th. The company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of $0.21 by $0.06. The firm earned $134.20 million during the quarter, compared to the consensus estimate of $130.67 million. Penumbra had a return on equity of 6.80% and a net margin of 3.03%. Penumbra's revenue for the quarter was up 22.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.15 earnings per share. View Penumbra's Earnings History.

When is Penumbra's next earnings date?

Penumbra is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Penumbra.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $535-540 million, compared to the consensus revenue estimate of $536.57 million.

What price target have analysts set for PEN?

8 Wall Street analysts have issued 12 month target prices for Penumbra's stock. Their predictions range from $152.00 to $185.00. On average, they expect Penumbra's share price to reach $170.17 in the next year. This suggests a possible upside of 17.6% from the stock's current price. View Analyst Price Targets for Penumbra.

What is the consensus analysts' recommendation for Penumbra?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Penumbra.

Has Penumbra been receiving favorable news coverage?

Press coverage about PEN stock has trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Penumbra earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Penumbra.

Are investors shorting Penumbra?

Penumbra saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 6,370,000 shares, an increase of 11.6% from the August 30th total of 5,710,000 shares. Based on an average daily volume of 560,200 shares, the days-to-cover ratio is currently 11.4 days. Approximately 19.9% of the shares of the company are short sold. View Penumbra's Current Options Chain.

Who are some of Penumbra's key competitors?

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), salesforce.com (CRM), Splunk (SPLK), Adobe (ADBE), Intuitive Surgical (ISRG), Twilio (TWLO), Paypal (PYPL) and Square (SQ).

Who are Penumbra's key executives?

Penumbra's management team includes the folowing people:
  • Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
  • Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
  • Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
  • Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
  • Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)

Who are Penumbra's major shareholders?

Penumbra's stock is owned by many different of retail and institutional investors. Top institutional investors include Pacer Advisors Inc. (0.03%), State of Alaska Department of Revenue (0.02%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.

Which major investors are buying Penumbra stock?

PEN stock was bought by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Crossmark Global Holdings Inc. and State of Alaska Department of Revenue. View Insider Buying and Selling for Penumbra.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $144.72.

How big of a company is Penumbra?

Penumbra has a market capitalization of $5.03 billion and generates $444.94 million in revenue each year. The company earns $6.60 million in net income (profit) each year or $0.51 on an earnings per share basis. Penumbra employs 2,200 workers across the globe.View Additional Information About Penumbra.

What is Penumbra's official website?

The official website for Penumbra is http://www.penumbrainc.com/.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]


MarketBeat Community Rating for Penumbra (NYSE PEN)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  520 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  709
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Special Dividends

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel